title: MCP-1 upregulates amylin expression in murine pancreatic β cells through ERK/JNK-AP1 and NF-κB related signaling pathways independent of CCR2.
abstract: BACKGROUND
  Amylin is the most abundant component of islet amyloid implicated in the development of type 2 diabetes. Plasma amylin levels are elevated in individuals with obesity and insulin resistance. Monocyte chemoattractant protein-1 (MCP-1, CCL2) is involved in insulin resistance of obesity and type 2 diabetes. We investigated the effect of MCP-1 on amylin expression and the underlying mechanisms with murine pancreatic β-cell line MIN6 and pancreatic islets.
  
  
  RESULTS
  We found that MCP-1 induced amylin expression at transcriptional level and increased proamylin and intermediate forms of amylin at protein level in MIN6 cells and islets. However, MCP-1 had no effect on the expressions of proinsulin 1 and 2, as well as prohormone convertase (PC) 1/3 and PC2, suggesting that MCP-1 specifically induces amylin expression in β-cells. Mechanistic studies showed that although there is no detectable CCR2 mRNA in MIN6 cells and islets, pretreatment of MIN6 cells with pertussis toxin inhibited MCP-1 induced amylin expression, suggesting that alternative Gi-coupled receptor(s) mediates the inductive effect of MCP-1. MCP-1 rapidly induced ERK1/2 and JNK phosphorylation. Inhibitors for MEK1/2 (PD98059), JNK (SP600125) or AP1 (curcumin) significantly inhibited MCP-1-induced amylin mRNA expression. MCP-1 failed to induce amylin expression in pancreatic islets isolated from Fos knockout mice. EMSA showed that JNK and ERK1/2 were involved in MCP-1-induced AP1 activation. These results suggest that MCP-1 induces murine amylin expression through AP1 activation mediated by ERK1/2 or JNK. Further studies showed that treatment of MIN6 cells with NF-κB inhibitor or overexpression of IκBα dominant-negative construct in MIN6 cells significantly inhibited MCP-1-induced amylin expression, suggesting that NF-κB related signaling also participates in MCP-1-induced murine amylin expression.
  
  
  CONCLUSIONS
  MCP-1 induces amylin expression through ERK1/2/JNK-AP1 and NF-κB related signaling pathways independent of CCR2. Amylin upregulation by MCP-1 may contribute to elevation of plasma amylin in obesity and insulin resistance.
authors: Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, Graduate School of the Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China.
authors: Kun
authors: K
authors: Cai
authors: Dongfei
authors: D
authors: Qi
authors: Xinwei
authors: X
authors: Hou
authors: Oumei
authors: O
authors: Wang
authors: Juan
authors: J
authors: Chen
authors: Bo
authors: B
authors: Deng
authors: Lihua
authors: L
authors: Qian
authors: Xiaolong
authors: X
authors: Liu
authors: Yingying
authors: Y
authors: Le
references: Diabetes Res Clin Pract. 1989 Sep 18;7(3):219-26
references: 2691219
references: Nature. 1988 Oct 13;335(6191):632-5
references: 3050530
references: Diabetes. 1989 Nov;38(11):1333-6
references: 2695369
references: Cancer Lett. 2002 Oct 8;184(1):89-96
references: 12104052
references: J Clin Invest. 2006 Jun;116(6):1494-505
references: 16691291
references: Endocrinology. 1992 Jan;130(1):43-52
references: 1727716
references: J Interferon Cytokine Res. 2002 May;22(5):517-26
references: 12060490
references: Biochim Biophys Acta. 2001 Nov 29;1537(3):179-203
references: 11731221
references: Obesity (Silver Spring). 2007 Aug;15(8):2006-11
references: 17712118
references: J Reprod Immunol. 2004 Aug;63(1):1-9
references: 15283999
references: Am J Transplant. 2003 Oct;3(10):1230-41
references: 14510696
references: Diabetologia. 2004 Feb;47(2):157-69
references: 14722650
references: J Leukoc Biol. 2004 Jun;75(6):1079-85
references: 15020650
references: Diab Vasc Dis Res. 2009 Oct;6(4):288-90
references: 20368224
references: Diabetologia. 1991 Feb;34(2):129-32
references: 2065848
references: Diabetologia. 2011 Mar;54(3):617-26
references: 21116608
references: Proc Natl Acad Sci U S A. 1987 Jun;84(11):3881-5
references: 3035556
references: Biochem Biophys Res Commun. 1989 Apr 28;160(2):961-7
references: 2655598
references: Mol Endocrinol. 2005 Aug;19(8):2154-63
references: 15802374
references: J Neurosci Res. 1996 Aug 15;45(4):382-91
references: 8872898
references: Gastroenterology. 2000 Nov;119(5):1209-18
references: 11054378
references: Diabetologia. 1990 Feb;33(2):118-20
references: 2184060
references: J Am Soc Nephrol. 2002 Jun;13(6):1534-47
references: 12039983
references: Diabetes. 2003 Nov;52(11):2759-66
references: 14578294
references: Nat Immunol. 2008 Jul;9(7):794-801
references: 18500346
references: J Clin Endocrinol Metab. 2004 Aug;89(8):3629-43
references: 15292279
references: Arterioscler Thromb Vasc Biol. 2002 Jun 1;22(6):914-20
references: 12067898
references: Diabetes. 2007 Sep;56(9):2284-94
references: 17563070
references: Diabetes Care. 2003 Oct;26(10):2883-9
references: 14514596
references: Curr Diab Rep. 2005 Feb;5(1):70-5
references: 15663921
references: Trends Mol Med. 2003 Jan;9(1):36-41
references: 12524209
references: Int J Obes (Lond). 2005 Jan;29(1):146-50
references: 15520826
references: Exp Gerontol. 2003 Apr;38(4):347-51
references: 12670620
references: Diabetes Res Clin Pract. 1992 Jan;15(1):97-102
references: 1541241
references: Endocrinology. 2005 Apr;146(4):1808-17
references: 15618358
references: Endocrinology. 1998 Dec;139(12):4928-35
references: 9832430
references: Endocrinology. 2006 May;147(5):2458-67
references: 16439461
references: Nat Immunol. 2007 Jun;8(6):592-600
references: 17468758
references: Hypertension. 1992 Jan;19(1 Suppl):I101-9
references: 1730446
references: Diabetologia. 2006 May;49(5):921-9
references: 16532324
references: J Biol Chem. 1997 Nov 7;272(45):28568-73
references: 9353321
references: J Biol Chem. 2000 May 19;275(20):15330-5
references: 10748090
references: Diabetologia. 1990 May;33(5):285-9
references: 2198187
references: Am J Physiol Endocrinol Metab. 2001 Nov;281(5):E938-45
references: 11595649
references: Proc Nutr Soc. 2009 Nov;68(4):378-84
references: 19698204
references: Int J Obes (Lond). 2006 Sep;30(9):1347-55
references: 16534530
references: Am J Physiol Endocrinol Metab. 2010 Jan;298(1):E99-E107
references: 19843871
references: Endocrinology. 2008 Feb;149(2):672-80
references: 17962352
references: Diabetes. 1990 May;39(5):634-8
references: 2185112
references: Curr Opin Lipidol. 2007 Jun;18(3):258-62
references: 17495598
references: J Biol Chem. 2006 Sep 8;281(36):26602-14
references: 16809344
references: Blood. 2001 Jan 15;97(2):359-66
references: 11154209
references: Diabetes. 1999 Feb;48(2):241-53
references: 10334297
references: Proc Natl Acad Sci U S A. 1987 Dec;84(23):8628-32
references: 3317417
references: J Biol Chem. 1996 Jan 26;271(4):1988-92
references: 8567648
references: Endocrinology. 2010 Mar;151(3):971-9
references: 20056828
references: Curr Drug Targets. 2011 Mar 1;12(3):332-47
references: 20955148
references: N Engl J Med. 2000 Aug 10;343(6):411-9
references: 10933741
references: Biochemistry. 2002 Sep 24;41(38):11338-43
references: 12234175
references: Diabetes. 2006 Jul;55(7):2106-14
references: 16804082
references: Diabetologia. 1992 Mar;35(3):291-3
references: 1563587
references: Cardiovasc Res. 2002 Nov;56(2):284-92
references: 12393099
references: Am J Physiol Endocrinol Metab. 2007 Dec;293(6):E1656-62
references: 17911343
references: Proc Natl Acad Sci U S A. 2003 Jun 10;100(12):7265-70
references: 12756299